Interferon beta-1a
Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
... (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis ...
6
A pilot study on the use of interferon beta-1a in early Alzheimer’s disease subjects
... features, interferon beta 1a (IFN β 1a), the well-established treatment for the prevention of disease progression and cognitive decline in MS patients, has never been used in ...β 1a in ...
6
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
... 20. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, ...
8
Renal thrombotic microangiopathy caused by interferon beta-1a treatment for multiple sclerosis
... A search in the French Pharmacovigilance Database using the terms “thrombotic microangiopathy”/“thrombotic thrombocytopenic purpura”/“hemolytic-uremic syndrome” combined with “interferon beta-1a” ...
6
A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis
... by Interferon beta-1a Subcutaneously in Multiple Sclerosis (PRISMS) trial and the EVidence of Interferon Dose-response: Euro- pean North American Comparative Efficacy (EVIDENCE) trial ...
12
The potential teratogenic effects of interferon beta-1a and interferon beta-1b on in vitro embryonic development
... Interferon beta-1b (IFNb-1b, Betaferon/Betaseron) was the first drug approved for the treatment of MS by Food and Drug Administration (FDA) in 1993 [21, 22, ...Later, interferon beta-1a ...
7
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart<sup>®</sup> in patients with multiple sclerosis
... istration of interferon beta-1a (INF β-1a) that is also able to monitor adherence objectively. The aim of this study was to describe adherence to INF β-1a using the said electronic ...
7
Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies
... ongoing interferon-beta treatment and 10 patients starting on interferon-beta) will receive standard interferon-beta-1a therapy for nine ...Bonn. ...
6
Adherence to subcutaneous interferon beta-1a treatment using an electronic injection device: a prospective open-label Scandinavian noninterventional study (the ScanSmart study)
... RebiSmart administers sc IFN beta-1a from multidose car- tridges. The device is designed to inject a fixed volume of 0.50 mL per injection. Each multidose cartridge was prefilled with 1.5 mL of solution ...
7
Interferon beta-1a for the maintenance of remission in patients with Crohn's disease: results of a phase II dose-finding study
... than 93% of patients in each treatment group (97% over- all) were white, with the remainder Hispanic. Patient demographic and clinical characteristics were well bal- anced, with no statistically significant differences ...
10
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis
... Specific interferon inducible genes have been identified that correlate with a better clinical response to IFN treatment in RRMS patients [16, 17], in addition it has been shown that pre-treatment baseline levels ...
8
PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
... PEG-IFN beta-1a in MS is being developed to achieve an optimized relationship between therapy-related side effects and pharmacokinetic/pharmaco- dynamic ...PEG-IFN beta-1a at a dose of 125 µg ...
8
Neopterin production and tryptophan degradation during 24 months therapy with interferon beta 1a in multiple sclerosis patients
... We found that the presence of disease progression and clinical relapses did not significantly affect biomar- ker levels. Furthermore, no differences in dose effect were observed between patients who had a clinical ...
9
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
... IFNβ, interferon beta; M, macrophage; MMP, matrix metalloproteinase; MS, multiple sclerosis; PEG, polyethylene glycol; PEG-IFNβ, pegylated interferon β; TIMP-1, tissue inhibitor of ...
14
Review of daclizumab and its therapeutic potential in the treatment of relapsing–remitting multiple sclerosis
... The DECIDE study – which is a Phase III multicenter, double-blind, randomized trial where daclizumab HYP is administered at a dose of 150 mg once every 4 weeks versus interferon beta-1a, which is ...
7
Alemtuzumab in the treatment of multiple sclerosis
... At this point, it is perhaps worth discussing the choice of comparator in these studies. Unlike most previous pivotal MS studies, an active comparator and not placebo was used in the study design. The comparator chosen ...
9
<p>Review Of The Safety, Efficacy And Tolerability Of Fingolimod In The Treatment Of Pediatric Patients With Relapsing-Remitting Forms Of Multiple Sclerosis (RRMS)</p>
... of interferon beta-1a ...vs interferon beta-1a ...to interferon beta-1a ...the interferon beta-1a ...the interferon ...
6
The role of glatiramer acetate in the early treatment of multiple sclerosis
... with interferon- beta-1b, less with interferon-beta-1a SQ and least with interferon-beta-1a ...monitor interferon neutralizing antibodies (NAbs) either ...
8
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
... Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta- 1a in patients wi[r] ...
22
Interferone und Natalizumab in der Behandlung der multiplen Sklerose (MS) Interferons and Natalizumab for Multiple Sclerosis
... Interferon beta-1a und Interferon beta-1b führten im Frühstadium einer MS ...verringerte Interferon beta-1a die Progredienz, über Interferon beta-1b ...
11